RRC ID 42185
著者 Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y.
タイトル Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
ジャーナル Am J Hematol
Abstract Impairment of fibrinolytic function plays an important role in the mechanism of thrombotic disorders in cancer patients. This study assessed the circulating level of thrombin-activatable fibrinolysis inhibitor in patients with lung cancer and its expression by several lung cancer cell lines. The plasma concentrations of thrombin-activatable fibrinolysis inhibitor were significantly increased in lung cancer patients compared to healthy subjects. The concentration of thrombin-activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non-responders. In vitro studies showed more expression of thrombin-activatable fibrinolysis inhibitor in small cell carcinoma than in adenocarcinoma cell lines and more expression in lung cancer cell lines sensitive to anti-cancer agents than in resistant cell lines. This study suggests that thrombin-activatable fibrinolysis inhibitor, in part secreted from lung cancer cells, may play a role in the pathogenesis of thrombotic disorders in lung cancer patients.
巻・号 76(3)
ページ 214-9
公開日 2004-7-1
DOI 10.1002/ajh.20079
PMID 15224354
MeSH Adenocarcinoma / blood Adult Aged Aged, 80 and over Antineoplastic Agents / pharmacology Carboxypeptidase B2 / blood* Carboxypeptidase B2 / genetics Carcinoma, Non-Small-Cell Lung / blood Carcinoma, Small Cell / blood Carcinoma, Squamous Cell / blood Drug Resistance, Neoplasm Female Gene Expression Humans Liver / metabolism Lung Neoplasms / blood* Male Middle Aged Reverse Transcriptase Polymerase Chain Reaction Tumor Cells, Cultured
IF 6.973
引用数 35
WOS 分野 HEMATOLOGY
リソース情報
ヒト・動物細胞 Hep G2